MCID: TXC002
MIFTS: 51

Toxic Encephalopathy malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Toxic Encephalopathy

Aliases & Descriptions for Toxic Encephalopathy:

Name: Toxic Encephalopathy 12 50 14
Neurotoxicity 12 51 14
Neurotoxicity Syndromes 50 42
Neurotoxicity Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3602
MeSH 42 D020258
NCIt 47 C27961
SNOMED-CT 64 19466003
ICD10 33 G92
UMLS 69 C0235032

Summaries for Toxic Encephalopathy

NINDS : 51 Neurotoxicity occurs when the exposure to natural or manmade toxic substances (neurotoxicants) alters the normal activity of the nervous system. This can eventually disrupt or even kill neurons, key cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from exposure to substances used in chemotherapy, radiation treatment, drug therapies, and organ transplants, as well as exposure to heavy metals such as lead and mercury, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness; loss of memory, vision, and/or intellect; headache; cognitive and behavioral problems; and sexual dysfunction. Individuals with certain disorders may be especially vulnerable to neurotoxicants.

MalaCards based summary : Toxic Encephalopathy, also known as neurotoxicity, is related to neuroblastoma and alzheimer disease. An important gene associated with Toxic Encephalopathy is HMOX1 (Heme Oxygenase 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Neuroscience. The drugs Oxaliplatin and Lacosamide have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and kidney, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A nervous system disease that results from exposure to neurotoxicants and is characterized by an altered mental status, memory loss, and visual problems.

Wikipedia : 71 Toxic encephalopathy is a neurologic disorder caused by exposure to neurotoxic organic solvent such as... more...

Related Diseases for Toxic Encephalopathy

Diseases related to Toxic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
id Related Disease Score Top Affiliating Genes
1 neuroblastoma 30.3 BDNF CASP3 CYCS NGF PRNP TH
2 alzheimer disease 11.2
3 phenylketonuria 11.0
4 hepatic encephalopathy 11.0
5 alzheimer disease-4 10.7
6 alzheimer disease, type 3 10.7
7 alzheimer disease 18 10.7
8 alzheimer disease-2 10.7
9 alzheimer disease 19, late onset 10.7
10 kernicterus 10.7
11 hyperbetaalaninemia 10.7
12 alzheimer disease mitochondrial 10.7
13 encephalopathy 10.6
14 neuronitis 10.4
15 urea cycle disorder 10.3 BDNF CASP3 NGF
16 retroperitoneal sarcoma 10.3 CASP3 GSTM1 GSTT1
17 pythiosis 10.2 ACHE MAOB TH
18 kashin-beck disease 10.2 ACHE BDNF TH
19 ornithinemia 10.2 CASP3 GSTM1 GSTT1
20 meier-gorlin syndrome 5 10.2 ACHE SLC6A3 TH
21 neonatal period electroclinical syndrome 10.2 BDNF GRIN2A GRIN2B
22 autism 19 10.2 MAOB SLC6A3 TH
23 nephrogenic adenoma of the urethra 10.2 MAOB SLC18A2 SLC6A3
24 mitochondrial dna depletion syndrome 3 10.2 SLC18A2 SLC6A3 TH
25 ectrodactyly-polydactyly 10.2 BDNF EPHX1 GRIN2A GRIN2B
26 basal cell carcinoma 3 10.2 GSTM1 GSTT1 SLC6A3
27 gallbladder adenoma 10.2 MAOB SLC18A2 SLC6A3 TH
28 idiopathic generalized epilepsy 10.2 BDNF CASP3 GRIN2B
29 chronic conjunctivitis 10.2 BDNF MAOB SLC18A2 SLC6A3
30 benign epilepsy with centrotemporal spikes 10.2 BDNF MAOB SLC18A2 TH
31 personality disorder 10.2 BDNF GRIN2A GRIN2B SLC6A3
32 hypereosinophilic syndrome 10.1 BDNF GSTM1 SLC6A3
33 cavernous hemangioma 10.1 SLC18A2 SLC6A3 TH
34 hiv-1 10.1
35 postmenopausal atrophic vaginitis 10.1 BDNF CASP3 CYCS NGF TH
36 cystadenoma 10.1 BDNF CASP3 CYCS NGF TH
37 eumycotic mycetoma 10.1 ACHE BDNF ITIH4 PRNP SLC6A3
38 hemochromatosis, type 2a 10.1 BDNF CASP3 MAOB SLC18A2 SLC6A3 TH
39 coenzyme q10 deficiency, primary, 1 10.0 ACHE MAOB PRNP SLC18A2 SLC6A3 TH
40 malignant ovarian mixed epithelial neoplasm 10.0 ABCB1 CASP3 CYCS
41 mucopolysaccharidosis is 10.0 BDNF CASP3 CYCS GRIN2A GRIN2B PRNP
42 long qt syndrome 5 9.9 BDNF CASP3 CYCS MAOB NGF PRNP
43 ellis-van creveld syndrome 9.9 BDNF GRIN2A GRIN2B MAOB SLC18A2 SLC6A3
44 preeclampsia/eclampsia 5 9.9 BDNF GRIN2A GRIN2B MAOB NGF SLC18A2
45 substance-induced psychosis 9.9 ACHE BDNF CASP3 MAOB NGF PRNP
46 schizophrenia 9.9 BDNF GRIN2A GRIN2B MAOB SLC18A2 SLC6A3
47 epithelioid type angiomyolipoma 9.8 ACHE BDNF HMOX1 MAOB NGF PRNP
48 spondyloarthropathy 1 9.7 ACHE BDNF CASP3 CYCS GRIN2A GRIN2B
49 shigellosis 9.7
50 cerebritis 9.7

Graphical network of the top 20 diseases related to Toxic Encephalopathy:



Diseases related to Toxic Encephalopathy

Symptoms & Phenotypes for Toxic Encephalopathy

MGI Mouse Phenotypes related to Toxic Encephalopathy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.35 SLC18A2 SLC6A3 TH ABCB1 ACHE BDNF
2 homeostasis/metabolism MP:0005376 10.24 PNPLA6 PRNP SLC18A2 SLC6A3 TH ABCB1
3 growth/size/body region MP:0005378 10.22 BDNF CASP3 CYCS GRIN2B HMOX1 NGF
4 cellular MP:0005384 10.21 BDNF CASP3 CYCS HMOX1 ITIH4 MAOB
5 cardiovascular system MP:0005385 10.11 ABCB1 CASP3 CYCS GRIN2B HMOX1 NGF
6 mortality/aging MP:0010768 10.07 CYCS GRIN2B HMOX1 NGF PNPLA6 PRNP
7 nervous system MP:0003631 10.03 ABCB1 ABCG2 ACHE BDNF CASP3 CYCS
8 integument MP:0010771 9.97 ABCG2 BDNF CASP3 GRIN2A NGF PNPLA6
9 no phenotypic analysis MP:0003012 9.61 ABCB1 ABCG2 ACHE BDNF CASP3 GRIN2B
10 taste/olfaction MP:0005394 8.92 BDNF CASP3 SLC18A2 SLC6A3

Drugs & Therapeutics for Toxic Encephalopathy

Drugs for Toxic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 641)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
2
Lacosamide Approved Phase 4 860352-01-8, 175481-36-4 219078
3
Fluorouracil Approved Phase 4,Phase 2,Phase 3 51-21-8 3385
4
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
5
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
6
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3 76-42-6 5284603
7
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
8
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1 24280-93-1 446541
10
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
11 Piracetam Approved Phase 4,Phase 3,Phase 2,Phase 1 7491-74-9
12
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
13
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
14
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
15
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 2180-92-9, 38396-39-3 2474
16
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 51-43-4 5816
17
Levobupivacaine Approved Phase 4 27262-47-1 92253
18
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
19
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
20
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
21
Desflurane Approved Phase 4 57041-67-5 42113
22
Isoflurane Approved, Vet_approved Phase 4,Phase 3 26675-46-7 3763
23
Sevoflurane Approved, Vet_approved Phase 4,Phase 3 28523-86-6 5206
24
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
25
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
26
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
27
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
28
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
29
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
30
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
31
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
32
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 84057-84-1 3878
33
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
34
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
35
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
36
Tenofovir Approved, Investigational Phase 4 147127-20-6 464205
37
Cobicistat Approved Phase 4 1004316-88-4
38
alemtuzumab Approved, Investigational Phase 4,Phase 1,Phase 2 216503-57-0
39
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
40
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 1 99-66-1 3121
41
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
42
Lorazepam Approved Phase 4 846-49-1 3958
43
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
44
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
45
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
46
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
47
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
48
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
49
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
50
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show top 50) (show all 684)
id Name Status NCT ID Phase
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
2 Cognitive and Behavioral Effects of Lacosamide Unknown status NCT01175954 Phase 4
3 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4
4 Colistin Pharmacokinetics in Continuous Renal Replacement Therapy Unknown status NCT02081560 Phase 4
5 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4
6 Use of a New Phototherapy Device (BBloo®) for the Treatment of Hyperbilirubinemia in the Newborn Infant Unknown status NCT02156050 Phase 4
7 Thermal QST for Interscale Block Evaluation Completed NCT02271867 Phase 4
8 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4
9 Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4
10 Taste, Smell and Chemotherapy (TASTY) Completed NCT01641172 Phase 4
11 Steroid Free Immunosuppression in Liver Transplantation Completed NCT00296244 Phase 4
12 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4
13 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4
14 Botulism Outbreak in Thailand (Episode II) Completed NCT00348426 Phase 4
15 Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection Completed NCT00662545 Phase 4
16 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease Completed NCT00862940 Phase 4
17 Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) Recruiting NCT03163277 Phase 4
18 PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Recruiting NCT02864030 Phase 4
19 Neurobiological and Cognitive Changes Following Exposure to Either Sevoflurane- or Propofol-based Anesthesia in Children Recruiting NCT03022240 Phase 4
20 Lipids and Neurological Complications in Liver Transplantation Recruiting NCT02544919 Phase 4
21 Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction Recruiting NCT01935128 Phase 4
22 IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy Recruiting NCT02918409 Phase 4
23 Optimum Thiamine Intervention (OpTIn) Trial Recruiting NCT02788552 Phase 4
24 SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Recruiting NCT02951559 Phase 4
25 Perampanel in Seizure Patients With Primary Glial Brain Tumors Recruiting NCT02363933 Phase 4
26 BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients Enrolling by invitation NCT02051062 Phase 4
27 A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/T Not yet recruiting NCT03067285 Phase 4
28 Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation Not yet recruiting NCT03076151 Phase 4
29 Seizure Treatment in Glioma Not yet recruiting NCT03048084 Phase 4
30 CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer Terminated NCT00129870 Phase 4
31 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4
32 Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4
33 Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors Unknown status NCT00566852 Phase 3
34 Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients Unknown status NCT00872352 Phase 3
35 Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain Unknown status NCT02084355 Phase 3
36 The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy Unknown status NCT02024191 Phase 3
37 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Unknown status NCT00274872 Phase 2, Phase 3
38 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Unknown status NCT01149109 Phase 3
39 Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy Unknown status NCT01645072 Phase 3
40 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3
41 Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) Unknown status NCT00103792 Phase 3
42 Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica Unknown status NCT01423591 Phase 3
43 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery Completed NCT00316914 Phase 3
44 Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer Completed NCT02468739 Phase 3
45 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed NCT01099449 Phase 3
46 Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. Completed NCT00305188 Phase 3
47 XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy Completed NCT00272051 Phase 3
48 Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel Completed NCT00039780 Phase 3
49 Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity Completed NCT01087658 Phase 3
50 Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer Completed NCT00363129 Phase 3

Search NIH Clinical Center for Toxic Encephalopathy

Cochrane evidence based reviews: neurotoxicity syndromes

Genetic Tests for Toxic Encephalopathy

Anatomical Context for Toxic Encephalopathy

MalaCards organs/tissues related to Toxic Encephalopathy:

39
Brain, Testes, Kidney, Cerebellum, Eye

Publications for Toxic Encephalopathy

Articles related to Toxic Encephalopathy:

(show top 50) (show all 130)
id Title Authors Year
1
Early Non-invasive Detection of Acute 1,2-Dichloroethane-induced Toxic Encephalopathy in Rats. ( 27815462 )
2016
2
Odorless inhalant toxic encephalopathy in developing countries household: Gas geyser syndrome. ( 27114653 )
2016
3
Neem oil poisoning - Case report of an adult with toxic encephalopathy. ( 27728581 )
2016
4
Poster 349 Toxic Encephalopathy and Rash Resulting from Paradichlorobenzene Inhalation: A Case Report. ( 27673102 )
2016
5
1,2-Dichloroethane-induced toxic encephalopathy: A case series with morphological investigations. ( 25743226 )
2015
6
The effect of hemoperfusion on patients with toxic encephalopathy induced by silkworm chrysalis ingestion. ( 26610794 )
2015
7
Toxic encephalopathy due to paradichlorobenzene toxicity: a case report and review of imaging characteristics. ( 26388394 )
2015
8
Capecitabine: toxic encephalopathy. ( 26688902 )
2015
9
A case of life-threatening acute kidney injury with toxic encephalopathy caused by Dioscorea quinqueloba. ( 25510780 )
2015
10
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose. ( 24822136 )
2014
11
Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology. ( 24631316 )
2014
12
Toxic encephalopathy due to colchicine--Gloriosa superba poisoning. ( 24591648 )
2014
13
Neem oil poisoning as a cause of toxic encephalopathy in an infant. ( 24522945 )
2014
14
Toxic encephalopathy after exposure to azacitidine. ( 25224457 )
2014
15
L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. ( 23961306 )
2013
16
Neem oil poisoning: Case report of an adult with toxic encephalopathy. ( 24339648 )
2013
17
MRI brain in monohalomethane toxic encephalopathy: A case report. ( 24347845 )
2013
18
Ethylene glycol toxic encephalopathy. ( 24347968 )
2013
19
Toxic encephalopathy. ( 22362126 )
2012
20
Toxic encephalopathy. ( 23251840 )
2012
21
Lethal toxic encephalopathy due to childhood shigellosis or Ekiri syndrome. ( 22177366 )
2012
22
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( 20926454 )
2011
23
Establishment of a poisoned animal model of toxic encephalopathy induced by 1,2-dichloroethane. ( 21329570 )
2011
24
Toxic encephalopathy. ( 21590623 )
2011
25
Toxic encephalopathy caused by occupational exposure to 1, 2-Dichloroethane. ( 20163807 )
2010
26
Margosa (Kohomba) oil induced toxic encephalopathy following home remedy for intestinal worms. ( 20052860 )
2009
27
An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? ( 19402572 )
2009
28
Toxic encephalopathy after taking dried seeds of Datura stramonium in two elderly subjects. ( 19702945 )
2009
29
Acute toxic encephalopathy due to the ingestion of Rhus extract. ( 19570681 )
2009
30
High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. ( 19596561 )
2009
31
Chronic toxic encephalopathy caused by occupational solvent exposure. ( 18409195 )
2008
32
Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. ( 19031955 )
2008
33
Psychosocial and cognitive rehabilitation of patients with solvent-induced chronic toxic encephalopathy: a randomised controlled study. ( 18560254 )
2008
34
Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. ( 17938643 )
2008
35
Severe reversible toxic encephalopathy induced by cisplatin in a patient with cervical carcinoma receiving combined radiochemotherapy. ( 17762922 )
2007
36
Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. ( 17762322 )
2007
37
Visual search and eye movements in patients with chronic solvent-induced toxic encephalopathy. ( 16765447 )
2006
38
Cognitive functioning in patients with suspected chronic toxic encephalopathy: evidence for neuropsychological disturbances after controlling for insufficient effort. ( 16484635 )
2006
39
Methadone intoxication in a child: toxic encephalopathy? ( 16970857 )
2006
40
Toxic encephalopathy and noise-induced hearing loss. ( 17851218 )
2006
41
Taurine induced toxic encephalopathy? ( 16844286 )
2006
42
Education for men with solvent-induced chronic toxic encephalopathy and their spouses. ( 15950841 )
2005
43
Psychological distress and coping in women married to men with a diagnosis of solvent-induced chronic toxic encephalopathy. ( 16101264 )
2005
44
Asterixis and toxic encephalopathy induced by gabapentin. ( 14687874 )
2004
45
Toxic encephalopathy induced by capecitabine. ( 15218302 )
2004
46
Solvent-related chronic toxic encephalopathy as a target in the worker's mental health research. ( 15558155 )
2004
47
Suboptimal performance on neuropsychological tests in patients with suspected chronic toxic encephalopathy. ( 12900068 )
2003
48
Psychological treatment of patients with chronic toxic encephalopathy: lessons from studies of chronic fatigue and whiplash. ( 12920327 )
2003
49
Solvent-induced toxic encephalopathy. ( 12024683 )
2002
50
Interaction between smoking and glutathione S-transferase polymorphisms in solvent-induced chronic toxic encephalopathy. ( 14992466 )
2002

Variations for Toxic Encephalopathy

Expression for Toxic Encephalopathy

Search GEO for disease gene expression data for Toxic Encephalopathy.

Pathways for Toxic Encephalopathy

Pathways related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 27)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.4 BDNF CASP3 CYCS GRIN2A GRIN2B SLC18A2
2 12.47 GRIN2A GRIN2B NGF PRNP TH
3
Show member pathways
12.37 ACHE GRIN2A GRIN2B MAOB SLC18A2 SLC6A3
4 12.09 BDNF CASP3 NGF TH
5 12.01 BDNF CASP3 GRIN2B NGF
6
Show member pathways
11.88 CASP3 CYCS GRIN2A GRIN2B
7 11.63 ABCB1 ABCG2 EPHX1
8 11.63 CASP3 CYCS SLC6A3 TH
9 11.58 ABCB1 ABCG2 HMOX1
10
Show member pathways
11.57 ABCG2 EPHX1 GSTM1 GSTT1
11 11.49 CASP3 CYCS GSTM1 GSTT1
12
Show member pathways
11.38 ACHE SLC6A3 TH
13
Show member pathways
11.38 BDNF CASP3 CYCS NGF
14 11.26 ABCG2 BDNF NGF SLC18A2 TH
15
Show member pathways
11.24 BDNF GRIN2A GRIN2B MAOB SLC18A2 SLC6A3
16 11.22 MAOB SLC6A3 TH
17 11.16 SLC18A2 SLC6A3 TH
18 11.13 ABCG2 GSTM1 GSTT1
19 11.03 EPHX1 GSTM1 GSTT1
20 11.01 ABCG2 EPHX1 HMOX1
21 10.97 ABCB1 CASP3 CYCS
22 10.81 ABCB1 GSTT1
23 10.77 MAOB TH
24 10.77 BDNF CASP3
25 10.73 ABCB1 ABCG2
26 10.69 ACHE TH
27 10.36 EPHX1 GSTM1

GO Terms for Toxic Encephalopathy

Cellular components related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 synaptic vesicle GO:0008021 9.33 GRIN2A SLC18A2 TH
2 cell surface GO:0009986 9.1 ABCB1 ACHE GRIN2A GRIN2B PRNP SLC6A3
3 NMDA selective glutamate receptor complex GO:0017146 8.96 GRIN2A GRIN2B

Biological processes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 response to toxic substance GO:0009636 9.78 EPHX1 MAOB SLC18A2
2 locomotory behavior GO:0007626 9.75 SLC18A2 SLC6A3 TH
3 response to wounding GO:0009611 9.74 ACHE CASP3 GRIN2A
4 response to organic cyclic compound GO:0014070 9.71 CASP3 EPHX1 SLC6A3 TH
5 response to corticosterone GO:0051412 9.6 MAOB TH
6 neurotrophin TRK receptor signaling pathway GO:0048011 9.59 CASP3 NGF
7 glutamate receptor signaling pathway GO:0007215 9.58 GRIN2A GRIN2B
8 neurotransmitter catabolic process GO:0042135 9.56 ACHE MAOB
9 learning or memory GO:0007611 9.56 CASP3 GRIN2A GRIN2B PRNP
10 dopamine biosynthetic process GO:0042416 9.55 SLC6A3 TH
11 response to ethanol GO:0045471 9.55 GRIN2A GRIN2B MAOB SLC6A3 TH
12 negative regulation of activated T cell proliferation GO:0046007 9.54 CASP3 PRNP
13 response to amphetamine GO:0001975 9.54 GRIN2A SLC18A2 TH
14 xenobiotic transport GO:0042908 9.52 ABCB1 ABCG2
15 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.51 CASP3 CYCS
16 neurotransmitter biosynthetic process GO:0042136 9.5 ACHE SLC6A3 TH
17 monoamine transport GO:0015844 9.49 SLC18A2 SLC6A3
18 dopamine catabolic process GO:0042420 9.48 MAOB SLC6A3
19 dopamine transport GO:0015872 9.46 SLC18A2 SLC6A3
20 aminergic neurotransmitter loading into synaptic vesicle GO:0015842 9.43 SLC18A2 TH
21 response to nicotine GO:0035094 9.26 CASP3 HMOX1 SLC6A3 TH
22 response to drug GO:0042493 9.17 ABCB1 ABCG2 CASP3 GRIN2A MAOB SLC6A3

Molecular functions related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 dopamine binding GO:0035240 9.26 SLC6A3 TH
2 xenobiotic-transporting ATPase activity GO:0008559 9.16 ABCB1 ABCG2
3 NMDA glutamate receptor activity GO:0004972 8.96 GRIN2A GRIN2B
4 monoamine transmembrane transporter activity GO:0008504 8.62 SLC18A2 SLC6A3

Sources for Toxic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....